Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
11 Jul 2023
11 Jul 2023
Historique:
received:
09
03
2023
accepted:
09
06
2023
medline:
12
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
epublish
Résumé
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ.1.1 and XBB.1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26.COV2.S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials.gov: NCT04889209.
Identifiants
pubmed: 37433788
doi: 10.1038/s41541-023-00693-z
pii: 10.1038/s41541-023-00693-z
pmc: PMC10336079
doi:
Banques de données
ClinicalTrials.gov
['NCT04889209']
Types de publication
Journal Article
Langues
eng
Pagination
98Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI148452
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148573
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148373
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00050
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148574
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148689
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148450
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007524
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148575
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148576
Pays : United States
Investigateurs
Evan J Anderson
(EJ)
Megan Berman
(M)
Kristen W Cohen
(KW)
Stephen De Rosa
(S)
Michelle Dickey
(M)
Jennifer Lee Dong
(JL)
Madison Ellis
(M)
Ann R Falsey
(AR)
Andrew B Fleming
(AB)
Katharine Floyd
(K)
Stephanie L Foster
(SL)
Daniel Graciaa
(D)
Ahsen Kahn
(A)
Satoshi Kamidani
(S)
Wendy A Keitel
(WA)
Lilin Lai
(L)
Sasha E Larsen
(SE)
Marina Lee
(M)
Kelly Manning
(K)
Kathryn M Moore
(KM)
Vivian Mulholland
(V)
Gysella B Muniz
(GB)
Seema Nayak
(S)
Asif Noor
(A)
Mit Patel
(M)
Laura Porterfield
(L)
Angie Price
(A)
Ian Shannon
(I)
Timothy R Shope
(TR)
Amber Stanford
(A)
Mehul S Suthar
(MS)
Anna Wald
(A)
Jennifer A Whitaker
(JA)
Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Lancet Infect Dis. 2022 Nov;22(11):1565-1576
pubmed: 35963274
Cell Rep Med. 2022 Jul 19;3(7):100679
pubmed: 35798000
Int J Infect Dis. 2023 Jan;126:64-72
pubmed: 36427701
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1545-1552
pubmed: 34735422
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1436-1441
pubmed: 36355612
Science. 2022 Aug 19;377(6608):821-822
pubmed: 35981045
N Engl J Med. 2023 Feb 16;388(7):662-664
pubmed: 36652339
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
N Engl J Med. 2022 Sep 29;387(13):1234-1236
pubmed: 36083119
N Engl J Med. 2021 Sep 23;385(13):1172-1183
pubmed: 34192426